The role of the renin-angiotensin system in atrial fibrillation and the therapeutic effects of ACE-Is and ARBS.
Atrial fibrillation (AF) is the most common rhythm disturbance in medical practice and represents a very expensive health problem. AF can be managed with the prevention of thromboembolism and either a rate control of rhythm strategy. As both strategies have important limitations, probably a preventative strategy in patients at risk of developing arrhythmia can be a more attractive option. The renin-angiotensin system (RAS) seems to be involved in the genesis of arrhythmia by the following two mechanisms: 1. the induction of atrial fibrosis and structural remodelling by mitogen-activated protein kinase (MAPK) expression and reduction of collagenase activity; 2. the induction of electrical remodelling by shortening of the atrial effective refractory period (AERP) and of the action potential duration. For these reasons it has been hypothesized that angiotensin-converting enzyme inhibitors (ACE-Is) and angiotensin-II receptor blockers (ARBs) may play a role in preventing AF recurrence. The aim of the present review was to analyse evidence supporting the usefulness of RAS inhibition in patients with AF in order to focus on which specific subset of patients it would most favour. After reviewing the literature, we conclude that, although many studies and meta-analysis have supported the advantage of RAS block in preventing AF recurrence, it is premature to recommend the use of ACE-Is and ARBs specifically for the prevention of AF. However we believe that as these drugs are safe and manageable, they should be considered the drugs of choice in patients with AF and coexisting clinical conditions such as hypertension, coronary disease, heart failure and diabetes mellitus.
Novo
Giuseppina
G
Division of Cardiology, Department of Internal Medicine and Cardiovascular Diseases, University of Palermo, Palermo, Italy. novog@mail.unipa.it
Guttilla
Daniela
D
Fazio
Giovanni
G
Cooper
Debbie
D
Novo
Salvatore
S
D000804:Angiotensin II / Q000627:therapeutic use*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000188:drug therapy* / Q000378:metabolism; D004554:Electric Countershock; D019317:Evidence-Based Medicine; D005838:Genotype; D006801:Humans; D020929:Mitogen-Activated Protein Kinase Kinases / Q000378:metabolism*; D012084:Renin-Angiotensin System / Q000187:drug effects*
D000806:Angiotensin-Converting Enzyme Inhibitors; D000889:Anti-Arrhythmia Agents; D000804:Angiotensin II; D020929:Mitogen-Activated Protein Kinase Kinases
Circulation. 1999 Jun 15;99(23):3028-35
10368121
J Am Coll Cardiol. 1998 Sep;32(3):695-703
9741514
Am J Med. 1995 May;98(5):476-84
7733127
Minerva Cardioangiol. 2007 Jun;55(3):311-5
17534249
J Am Coll Cardiol. 2005 Mar 1;45(5):712-9
15734615
Hypertens Res. 2006 Apr;29(4):277-84
16778335
Circ Res. 1993 Sep;73(3):413-23
8348686
Lancet. 1999 Nov 20;354(9192):1751-6
10577635
Am Heart J. 2006 Jun;151(6):1187-93
16781218
JAMA. 2004 Nov 24;292(20):2471-7
15562125
Arch Intern Med. 1994 Jul 11;154(13):1449-57
8018000
Circulation. 2000 Jun 13;101(23):2678-81
10851203
Cardiovasc Res. 1993 Mar;27(3):341-8
8490934
N Engl J Med. 2008 Apr 10;358(15):1547-59
18378520
Circulation. 2002 Jul 16;106(3):331-6
12119249
Circulation. 1999 Jul 27;100(4):376-80
10421597
Circulation. 2000 Sep 19;102(12):1454-60
10993867
Lancet. 1999 Feb 20;353(9153):611-6
10030325
Am Heart J. 2005 Mar;149(3):548-57
15864246
Pacing Clin Electrophysiol. 2003 Jan;26(1P2):295-8
12687832
Am Heart J. 2006 Aug;152(2):217-22
16875900
Circulation. 2003 Jun 17;107(23):2926-31
12771010
J Mol Cell Cardiol. 1995 Sep;27(9):1905-14
8523451
Eur Heart J. 2006 Aug;27(15):1841-6
16825288
Am Heart J. 2004 Jul;148(1):52-61
15215792
Circ Res. 1990 Dec;67(6):1355-64
1700933
Lancet. 2000 Nov 25;356(9244):1789-94
11117910
J Hum Genet. 2002;47(4):184-9
12166654
J Am Coll Cardiol. 2003 Nov 19;42(10):1785-92
14642689
Am J Cardiol. 2007 Jul 15;100(2):247-52
17631079
J Cardiovasc Med (Hagerstown). 2006 Jan;7(1):29-38
16645357
Circulation. 2001 Nov 20;104(21):2608-14
11714658
Circulation. 1997 Aug 19;96(4):1180-4
9286947
JAMA. 2001 May 9;285(18):2370-5
11343485
J Am Coll Cardiol. 2005 Jun 7;45(11):1832-9
15936615
Eur Heart J. 2003 Dec;24(23):2090-8
14643269
Eur Heart J. 2006 Aug;27(16):1979-2030
16885201
Circulation. 2006 Mar 14;113(10):1278-86
16534027
Circulation. 2000 Jun 6;101(22):2612-7
10840013
Am J Med. 2002 Oct 1;113(5):359-64
12401529
Circulation. 1997 Oct 7;96(7):2455-61
9337224
J Renin Angiotensin Aldosterone Syst. 2004 Sep;5(3):114-20
15526246
Am Heart J. 2004 Jan;147(1):121-6
14691429
Am Heart J. 2006 Jul;152(1):86-92
16838426
J Mol Cell Cardiol. 1994 Jul;26(7):809-20
7966349
J Am Coll Cardiol. 2005 Mar 1;45(5):705-11
15734614
Heart Rhythm. 2007 Jun;4(6):743-9
17556195
J Clin Pharmacol. 2006 Jan;46(1):21-8
16397280
Eur Heart J. 2006 Sep;27(17):2062-8
16891381
Circulation. 2004 Apr 6;109(13):1640-6
15023884